The Efficacy and Tolerability of Acarbose in Healthy Individuals

• Status: Active, not recruiting
• Trial end date: 2022-10-01
• Target enrollment: 0
• Participant gender: All

Summary

A Prospective Trial for Acarbose in Healthy Individuals Assessing Safety and Efficacy in Reducing Glucose Spikes After Carbohydrate Consumption.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AgelessRx
• Treatments: Acarbose

Criteria

Inclusion Criteria:

1. Age 18-85

2. Any sex

3. Any ethnicity

4. Interest in taking Acarbose off-label

5. Approved by the AgelessRx Medical team to take Acarbose

6. Willing and technically able to use and operate a CGM

7. Own a CGM-compatible phone

8. Relatively good health with only well-managed chronic diseases (hypertension, coronary artery disease, type II diabetes, etc.) clinically stable

9. Adequate cognitive function to be able to give informed consent

Exclusion Criteria:

1. Diabetes of any type

2. Taking metformin or any other glucose lowering medication

3. Any uncontrolled endocrine disorder (thyroid, pancreatic, adrenal, etc...)

4. Active malignancy of any kind

5. Clinically relevant renal or kidney disease or dysfunction

6. History of eating disorder

7. Taking any medication, or has any medical condition that might interfere with the action of acarbose of the CGM sensor